Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia (Q28213633)

https://api.crossref.org/works/10.1111/J.1365-2141.2004.05277.X

Efficacy and safety of low-dose aspirin in polycythemia vera

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2004.05277.X

Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2004.05277.X

The risk of thrombosis in essential thrombocythemia and polycythemia vera

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2004.05277.X

Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2004.05277.X

Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Thrombocythaemia and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Therapeutic apheresis in hematological and oncological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

21 January 2018

The Budd-Chiari syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

No treatment for low-risk thrombocythaemia: results from a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

The effects of anagrelide on human megakaryocytopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Long-term use of anagrelide in young patients with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Experimental study of transplacental passage of alpha interferon by two assay techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Platelet Hyperaggregability and Thrombosis in Patients with Thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X

Should a platelet limit of 600 x 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05277.X